Phase II trial of niraparib for BRCA-mutated biliary tract, pancreatic and other gastrointestinal cancers: NIR-B.
Kawamoto Y, Morizane C, Komatsu Y, Kondo S, Ueno M, Kobayashi S, Furukawa M, Lee L, Satoh T, Sakai D, Ikeda M, Imaoka H, Miura A, Hatanaka Y, Yokota I, Nakamura Y, Yoshino T.
Kawamoto Y, et al. Among authors: furukawa m.
Future Oncol. 2024 Apr 17. doi: 10.2217/fon-2023-0348. Online ahead of print.
Future Oncol. 2024.
PMID: 38629456
Review.